Progyny (PGNY) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PGNY shares.
View PGNY analyst ratings or view top-rated stocks.

6 equities research analysts have issued twelve-month price targets for Progyny's shares. Their PGNY share price forecasts range from $34.00 to $62.00. On average, they predict the company's share price to reach $49.43 in the next year. This suggests a possible upside of 49.4% from the stock's current price.
View analysts price targets for PGNY or view top-rated stocks among Wall Street analysts.

Progyny's stock was trading at $31.15 at the beginning of 2023. Since then, PGNY stock has increased by 6.2% and is now trading at $33.09.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PGNY earnings forecast.

Progyny, Inc. (NASDAQ:PGNY) released its earnings results on Thursday, August, 3rd. The company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.05. The business earned $279.40 million during the quarter, compared to the consensus estimate of $261.91 million. Progyny had a trailing twelve-month return on equity of 12.19% and a net margin of 5.15%. The company's quarterly revenue was up 43.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.09 earnings per share.

ETFs with the largest weight of Progyny (NASDAQ:PGNY) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), Aztlan Global Stock Selection DM SMID ETF (AZTD), BNY Mellon Women's Opportunities ETF (BKWO), SPDR S&P Health Care Services ETF (XHS), Thrivent Small-Mid Cap ESG ETF (TSME), Harbor Corporate Culture Small Cap ETF (HAPS), Nuveen Small Cap Select ETF (NSCS) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

Progyny updated its FY23 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $0.50-$0.53 for the period, compared to the consensus earnings per share estimate of $0.47. The company issued revenue guidance of $1.075-$1.09 billion, compared to the consensus revenue estimate of $1.06 billion.

25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD).

(PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Progyny trades on the NASDAQ under the ticker symbol "PGNY."

Progyny's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (10.02%), KPCB XIII Associates LLC (5.38%), Clearbridge Investments LLC (4.24%), JPMorgan Chase & Co. (2.80%), State Street Corp (2.68%) and Thrivent Financial for Lutherans (2.38%). Insiders that own company stock include Beth C Seidenberg, Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Lisa Greenbaum, Mark S Livingston, Norman Payson, Perkins Caufield & Bye Kleiner, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc.
View institutional ownership trends.

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PGNY stock can currently be purchased for approximately $33.09.

Progyny (NASDAQ:PGNY) has a market capitalization of $3.16 billion and generates $786.91 million in revenue each year. The company earns $30.36 million in net income (profit) each year or $0.49 on an earnings per share basis.

The company employs 393 workers across the globe.

Progyny's mailing address is 1359 BROADWAY, NEW YORK NY, 10018. The official website for the company is www.progyny.com. The company can be reached via phone at 212-888-3124 or via email at investors@progyny.com.